Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, accounting for 80-85% of all thyroid malignancies. It originates from follicular cells and is histologically characterized by papillary structures with characteristic nuclear features (ground-glass nuclei, nuclear grooves, pseudoinclusions). Most commonly occurs between ages 30-50 and in women (F:M = 3:1). Incidence is markedly increased in radiation-exposed populations. Lymphatic spread is the dominant metastatic route — cervical lymph node metastasis is present in 30-80% of cases at diagnosis. Despite this, it has an excellent prognosis (10-year survival >95%). In ACR TI-RADS v2017, classic PTC findings (microcalcifications, taller-than-wide shape, irregular margins, marked hypoechogenicity) define the highest suspicion category TR5.
Age Range
20-60
Peak Age
40
Gender
Female predominant
Prevalence
Common
PTC develops from thyroid follicular epithelium and is most commonly associated with activation of the MAPK signaling pathway. BRAF V600E mutation is found in 40-60% of cases and is the most frequent genetic alteration — this mutation constitutively activates RAF kinase, increases cell proliferation, and inhibits apoptosis. RAS mutations and RET/PTC rearrangements are other common genetic events. Radiation exposure (especially in childhood) increases the risk of RET/PTC rearrangements — the post-Chernobyl increase in PTC incidence is explained by this. Psammoma bodies (concentric calcified lamellar structures) form from dystrophic calcification at the tips of papillary structures — these structures appear as microcalcifications on ultrasonography and have high specificity (95%+) for PTC. The tumor's tendency for lymphatic spread results from lymphangiogenesis stimulated by VEGF-C and VEGF-D expression — therefore, cervical lymph node metastasis is common even at very early stages. The taller-than-wide growth pattern reflects the tumor's invasive growth penetrating normal tissue planes.
Punctate echogenic foci <1mm within the nodule, without comet-tail artifact — representing psammoma bodies. The most specific single finding for PTC (85-95% specificity). Dystrophic calcification accumulating at the tips of papillary structures, the pathological signature finding of PTC. Microcalcification+marked hypoechogenicity+taller-than-wide+irregular margins combination → TI-RADS TR5 = highly suspicious → FNAB indication.
Punctate echogenic foci smaller than 1mm without comet-tail artifact within the nodule — representing psammoma bodies. The most specific ultrasonographic finding for PTC (specificity 85-95%, sensitivity 26-59%). Microcalcifications are dystrophic calcification foci accumulating at the tips of papillary structures. Posterior acoustic shadowing is mostly absent (size too small). Differentiation from comet-tail artifact is critical: NO V-shaped bright tail behind microcalcification, it is fixed in position and does not shift with movement. In TI-RADS v2017, microcalcification scores 3 points (highest echogenic foci score).
Report Sentence
Multiple punctate echogenic foci (<1mm, microcalcifications) are identified within the nodule, consistent with psammoma bodies; papillary thyroid carcinoma should be strongly considered (TI-RADS TR5).
PTC appears on ultrasonography as a solid, markedly hypoechoic (echogenicity equal to or lower than surrounding strap muscles), taller-than-wide shaped nodule with irregular/lobulated margins. This combination yields the highest total score in TI-RADS v2017 (composition 2 + echogenicity 3 + shape 3 + margin 2 + microcalcification 3 = 13 points = TR5). Solid composition reflects the dense cellular packing of papillary structures. Taller-than-wide shape indicates the tumor's invasive growth penetrating tissue planes. Irregular margins represent infiltration into surrounding thyroid parenchyma and capsule.
Report Sentence
A solid, markedly hypoechoic, taller-than-wide configured nodule measuring …x…x… mm with irregular margins and microcalcifications is identified in the right/left thyroid lobe, highly consistent with papillary thyroid carcinoma (TI-RADS TR5); FNAB is recommended.
On color Doppler, PTC demonstrates markedly increased, irregular intranodular vascularity. Tumor neoangiogenesis creates vessels with irregular caliber and disrupted branching pattern — 'chaotic vascularity'. Intranodular vascularity does not directly score points in TI-RADS but is a finding supporting malignancy suspicion. Perinodular vascularity may also accompany but the dominant pattern is intranodular. Similar hypervascular pattern is seen in metastatic cervical lymph nodes — peripheral (subcapsular) vascularity with loss of hilar vascularity.
Report Sentence
Color Doppler examination demonstrates markedly increased, irregular intranodular vascularity (chaotic pattern) in the nodule, a finding favoring malignancy.
Cervical lymph node metastases of PTC characteristically contain a cystic component (in 30-50% of cases) — this results from cystic degeneration of papillary tumor tissue and has high specificity for PTC metastasis. Metastatic nodes also demonstrate microcalcifications, loss of hilar vascularity (replaced by peripheral vascularity), rounding (short/long axis ratio >0.5), and loss of normal echogenic hilum. Most commonly involved lymph node stations: Level III, IV, and VI (central compartment). Lateral compartment (Level II-V) and central compartment (Level VI) should be carefully scanned.
Report Sentence
Pathological lymph node(s) measuring …x… mm containing cystic component and microcalcifications with loss of hilar vascularity are identified at cervical Level III/IV/VI, consistent with papillary thyroid carcinoma lymph node metastasis.
On contrast-enhanced CT, PTC typically appears as a solid nodule with less enhancement (hypodense) than normal thyroid parenchyma. Fine punctate calcifications (microcalcifications) can be detected on CT but resolution is lower than US. Extrathyroidal extension (tracheal invasion, esophageal invasion, recurrent laryngeal nerve proximity), metastatic cervical lymph nodes, and distant metastases are assessed with CT. CT is used as a preoperative staging tool to guide surgery — particularly complementing US in Level VI (central compartment) lymph node evaluation.
Report Sentence
On contrast-enhanced CT, a solid nodule measuring …x…x… mm with less enhancement than surrounding parenchyma and fine calcifications is identified in the right/left thyroid lobe, consistent with thyroid carcinoma; evaluation for extrathyroidal extension and cervical lymph nodes is recommended.
On preoperative scintigraphy, PTC almost always appears as a cold (hypofunctioning) nodule. However, after total thyroidectomy, residual tumor tissue and metastases are evaluated with I-131 whole body scintigraphy. PTC generally maintains sufficient NIS expression as it originates from follicular cells, and shows I-131 uptake — this is used for both diagnostic and therapeutic purposes. Residual uptake in the postoperative thyroid bed may represent residual tumor or normal thyroid remnant. Distant metastases (pulmonary micronodular, bone) can be detected on I-131 scintigraphy.
Report Sentence
On I-131 whole body scintigraphy, focal radiopharmaceutical uptake is noted in the thyroid bed/cervical region/lungs, consistent with residual/metastatic papillary thyroid carcinoma.
Criteria
Typical papillary architecture + characteristic nuclear features. Most common subtype (60-70%). BRAF V600E mutation most frequent in this type.
Distinct Features
Classic appearance on US: solid, hypoechoic, with microcalcifications. Lymphatic metastasis common. RAI-avid. Excellent prognosis.
Criteria
Follicular growth pattern + papillary nuclear features. In encapsulated form (NIFTP — noninvasive follicular thyroid neoplasm with papillary-like nuclear features) prognosis is excellent.
Distinct Features
May resemble follicular adenoma on US: encapsulated, hypoechoic, microcalcifications rarely seen. In NIFTP, surgery is curative, no RAI needed.
Criteria
Cells with height ≥3 times their width with oncocytic appearance. More than 30% of tumor must consist of tall cells. BRAF V600E mutation in nearly all cases.
Distinct Features
More aggressive behavior: increased risk of extrathyroidal extension, vascular invasion, and distant metastasis. Not significantly different from classic PTC on imaging.
Criteria
Predominantly cystic presentation of PTC. Papillary tumor tissue present in cyst wall or intracystic septum. May be confused with colloid cyst on biopsy.
Distinct Features
Mural nodule or papillary projection in cyst wall/septum is important distinguishing clue. High false-negative risk on FNAB — biopsy should target solid component.
Distinguishing Feature
Follicular carcinoma does not contain microcalcifications, taller-than-wide shape is rarer, it is encapsulated with smooth margins. Hematogenous metastasis (bone, lung) is dominant; lymphatic metastasis is rare. In PTC, microcalcification + lymphatic metastasis is dominant.
Distinguishing Feature
Medullary carcinoma shows coarse calcifications (larger than microcalcifications), markedly hypoechoic, hypervascular. Serum calcitonin is elevated (normal in PTC). C-cell origin (not follicular cell). RET proto-oncogene mutation (MEN2).
Distinguishing Feature
In colloid nodule, spongiform pattern + comet-tail artifact + cystic dominant structure = benign (TI-RADS TR1). In PTC, solid + microcalcification (no comet-tail) + taller-than-wide + irregular margin = malignant (TI-RADS TR5).
Distinguishing Feature
Anaplastic carcinoma is a very rapidly growing, large, unencapsulated, markedly invasive mass. Usually seen in elderly patients (>60 years). Extrathyroidal extension is common. PTC shows younger age, slower growth, and better prognosis. No RAI uptake in anaplastic carcinoma.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralFNAB is recommended for PTC suspicion (TI-RADS TR4-TR5). If cytology is Bethesda V-VI, surgery (total thyroidectomy ± central/lateral lymph node dissection) is planned. Preoperative US should scan bilateral thyroid lobes + central and lateral cervical lymph node regions. Preoperative CT staging is performed in large tumors (>4cm) or suspected extrathyroidal extension (iodinated contrast may delay RAI therapy 4-8 weeks). RAI (I-131) therapy is administered based on post-surgical risk stratification. Follow-up: serum thyroglobulin + neck US (every 6 months in first year, then annually). BRAF V600E positive tumors may be more aggressive — recurrence risk is 20-30% higher. Prognosis is generally excellent: 10-year survival >98% in stage I-II patients.
Papillary thyroid carcinoma is the most common thyroid cancer but has an excellent prognosis (10-year survival >95%). Treatment is total thyroidectomy + radioactive iodine ablation. Despite frequent cervical LAP, distant metastasis is rare. ACR TI-RADS TR5 (highly suspicious).